IOmx Therapeutics Initiates Phase Ib with OMX-0407

iOmx Therapeutics AG has launched Phase Ib of its clinical trial for OMX-0407, following successful doses in Phase Ia. Data showed that the drug demonstrated a favorable safety profile and anti-tumor activity, including one complete response in a high-need medical situation.

During Phase Ib, iOmx will expand its study to include patients with kidney cancer and angiosarcoma. The aim is to evaluate the drug's efficacy and safety in larger patient groups. Topline data indicates that OMX-0407 was safe and well-tolerated, with solid signs of anti-cancer activity.

The expansion phase will be conducted in major oncology centers. Primary endpoints include objective response rate, while secondary objectives focus on duration of response and patient survival. The company expects to release proof-of-concept data by early 2026.